MultipleSkleroseDokumentationssystem 3D

Authors: T Schultheiß R Kempcke F Kratzsch M Eulitz M Pette H Reichmann T Ziemssen

Publish Date: 2011/10/20

Volume: 83, Issue: 4, Pages: 450-457

PDF Link

Abstract

MSDS 3D integriert Daten von Patienten betreuenden Ärzten und MSSchwestern 3 Dimensionen Es erlaubt die Dokumentation von Vorstellungsterminen Visiten sowie Untersuchungsbefunden über interaktive Bildschirmoberflächen Touchscreens Ein spezifisches in die aktuelle Version von MSDS 3D integriertes Modul dient der monatlichen Evaluation von Patienten unter der Therapie mit Natalizumab Die Entwicklung einer Checkliste für Zeichen einer progressiven multifokalen Leukenzephalopathie PML sowie eines NatalizumabFragebogens könnten dazu beitragen diese in Frühstadien gut therapierbare Erkrankung zeitnah zu erkennenThe increasing therapeutic options for relapsingremitting multiple sclerosis require a specific treatment and risk management to recognize the individual response as well as potential side effects To switch from pure MS documentation to MS management by implementing a new multiple sclerosis management and documentation tool may be of importanceMSDS 3D allows documentation and visualization of visit schedules and mandatory examinations via defined study modules by integration of data input from patients attending physicians and MS nurses It provides forms for the documentation of patient visits as well as clinical and diagnostic findings Information is collected via interactive touch screens A specific module which is part of MSDS 3D’s current version allows the monthly monitoring of patients under treatment with natalizumab A checklist covering clinical signs of progressive multifocal leukoencephalopathy PML and a detailed questionnaire about the handling of natalizumab in practice have additionally been addedThe MS patient management system MSDS 3D has successfully been implemented and is currently being evaluated in a multicentre setting Advanced assessment of patient data may allow improvements in clinical practice and research work The addition of a checklist and a questionnaire into the natalizumab module may support the recognition of PML during its early treatable course

Keywords: